Testing HLA-B∗15:02

Neurology

Volumn 86, Issue 12, 2016, Pages 1080-1081

  Marson, Anthony ^a   Guerrini, Renzo ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA B15 ANTIGEN; PHENYTOIN; VALPROIC ACID;

ALLELE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; EDITORIAL; EPIDERMOLYSIS; EPILEPSY; ETHNIC GROUP; GENETIC MARKER; HEALTH CARE POLICY; HLA TYPING; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEVENS JOHNSON SYNDROME; TURNAROUND TIME; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETIC SCREENING; GENETICS; MALE;

COST-BENEFIT ANALYSIS; EPILEPSY; FEMALE; GENETIC TESTING; HUMANS; MALE; PHARMACOGENETICS;

EID: 84961620272     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002500     Document Type: Editorial

References (4)

1. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428: 486.
2. US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) [online]. Available at: http://www.fda.gov/.Drugs/DrugSafety/Postmarketdrugsafetyinformationfor PatientsandProviders/ucm124718.htm. Accessed November 26, 2014.
3. Chen Z, Liew D, Kwan P. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016; 86: 1086-1094.
4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372: 793-795.